SUVENPHAR Stock Analysis: Is It the Right Time to Buy or Sell?

                                                            Technical Indicators Overview:

1. Ichimoku Cloud:

   • Price is currently above the Ichimoku cloud, which indicates a bullish trend.
   • The conversion line (9-day) is at 1199.00, while the base line (26-day) is at 1131.50, suggesting a short-term bullish momentum.

2. Moving Averages:

   • 21-day MA: 1123.97 (Price is above this, showing strength).
   • 50-day MA: 1106.95 (Price is also above this, confirming bullishness).
   • 200-day MA: 1047.25 (A long-term support level).

3. RSI (Relative Strength Index): 61.38

   • RSI is above 50, which is bullish, but not yet overbought.
   • A rise above 70 would indicate an overbought condition, while a drop below 50 could be a warning.

4. MACD (Moving Average Convergence Divergence):

   • MACD Line: 28.50 (Above zero, bullish momentum).
   • Signal Line: 13.91 (MACD is above the signal line, a buy signal).
   • Divergence: 14.59, indicating increasing strength.

5. Volume Analysis:

   • There was a recent spike in volume, indicating fresh buying interest.
   • Sustained higher volume would support further upside.

---

Prediction & Recommendation:

Bullish Scenario (Buy Recommendation)

• The stock is trading above all key moving averages and has broken above the Ichimoku cloud, which is a bullish sign.
• If the stock sustains above 1210-1230, it can move towards 1300-1350 levels in the short term.
• Ideal Buy Zone: 1190-1210 (Near support levels).
• Target Levels: 1300 / 1350 / 1400
• Stop Loss: Below 1100 (200-day MA is key support).

Bearish Scenario (Sell Recommendation)

• If the stock fails to sustain above 1200 and drops below 1100, it may turn bearish.
• If it closes below 1050, a deeper correction towards 950-900 levels is possible.
• Sell Below: 1100
• Target: 1050 / 1000
• Stop Loss: Above 1220 (If shorting).

---

Conclusion:

• The trend is bullish, and current levels favor a buy-on-dips strategy.
• Wait for confirmation if entering a new long position, ensuring the stock holds above 1190-1210.
• Watch for increased volume to confirm strong buying interest.

📈 Recommendation: Buy on dips near 1190-1210 with targets of 1300-1350. Stop-loss at 1100. 🚀

Best Time to Buy Glenmark Pharmaceuticals Ltd.

Company at a Glance:

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with operations in over 80 countries and a presence in generics, specialty, and over-the-counter (OTC) products.

Listed among the top 50 Generics and biosimilar companies in the world

Integrated throughout the pharmaceutical value chain, with a strong presence in drug discovery, API, and finished dose formulations.

With drugs in various stages of clinical development, the institute has established research excellence in both novel small molecule and biologics research.

The fastest-growing pharmaceutical company among the top 20 in the Indian pharmaceutical market In terms of volume, it ranks 15th among US generic pharma companies. 14 world-class manufacturing plants

        

Financial Highlights

Criteria	Mar 16	Mar 17	Mar 18	Mar 19	Mar 20	Mar 21	Mar 22	TTM	Chart
Price	795.05	857.75	547.45	653.15	205.85	464.7	442
Sales +	7562	9079	9074	9865	10641	10944	12305	12636.0
Sales Growth(YOY)	15.2%	20.1%	-0.1%	8.7%	7.9%	2.8%	12.4%	0.13
Sales Growth(Cagr-2 YOY)	12.2%	17.6%	9.5%	4.2%	8.3%	5.3%	7.5%	0.07
Profit before tax	1,044	1,491	1,119	1,301	1,096	1,382	1,441	1629.0
PBT Margin	14%	16%	12%	13%	10%	13%	12%	0.13
Tax %	29%	26%	28%	29%	29%	30%	31%
Net Profit	743	1109	804	925	776	970	994	953.0
Net Profit Margin	9.8%	12.2%	8.9%	9.4%	7.3%	8.9%	8.1%	0.08
% Profit Growth YOY	256%	49%	-28%	15%	-16%	25%	2%	-0.04
EPS in Rs	26.33	39.29	28.49	32.78	27.5	34.38	33.37	31.22
Price to earning	30.2	21.8	19.2	19.9	7.5	13.5	13.2	14.88
Consolidated Figures in Rs. Crores

Total Revenue, Net Profit.& Return of equity(ROE) Comparison with Average Values:

Average Total Revenue Annual Cr (Annual | in cr ₹)				Average Net Profit Annual Cr (Annual | in cr ₹)				Average ROE Annual % (Annual | in cr ₹)
1Yrs	3Yrs	5 Yrs	7 Yrs	1Yrs	3Yrs	5 Yrs	7 Yrs	1Yrs	3Yrs	5 Yrs	7 Yrs
12305.0	11961.7	11278.2	10649.1	994.0	972.3	923.6	933	10.36 %	12.29 %	13.79 %	16.3 %

Conclusive Summary:-

• Total Revenue Annual Cr growth is higher than historical averages.
• Net Profit Annual Cr growth is stable compared to historical averages.
• ROE Annual % is growing slower than historical averages.

Valuation & Fundamental Price Target

The market expects 7 % revenue and 7.5% PAT CAGRs over FY22-FY25E along with EBITDA margin at ~18-20%

Maintain BUY with a target price of Rs525/share based on 12x Sep'24E earnings. Over the last five years, the stock has traded at an average P/E of 17.3x.

Technical breakout to Buy 

Technically the stock is a very strong candidate for a good Buy. From 18 Apr '22, Glenmark Pharma successfully formed a Cup & Handle pattern. last week after giving a strong breakout above Rs. 443

Level , sustained for 3 days at the present level of Rs. 464.7.

This good time to buy this stock at this level & buy on dips up to Rs. 412 with a stop loss of Rs. 410.

Technical Tergerget is Rs. 550.

Happy investing.